<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159590">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01689194</url>
  </required_header>
  <id_info>
    <org_study_id>CRCST-L-0007</org_study_id>
    <secondary_id>H-1204-103-407</secondary_id>
    <nct_id>NCT01689194</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Research Center for Solid Tumor, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is Phase II trial for evaluating efficacy of induction chemotherapy
      using Genexol-PM + cisplatin for locally advanced head and neck cancer. The investigators
      try to evaluate response rate of Genexol-PM + cisplatin chemotherapy, and safety profile.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>response rate</measure>
    <time_frame>every 2 cycles, 6wk later after chemotherapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locoregional control rate</measure>
    <time_frame>every 3wk (every cycle)</time_frame>
    <safety_issue>No</safety_issue>
    <description>NCI CTCAE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>every 3wk (every cycle)</time_frame>
    <safety_issue>No</safety_issue>
    <description>EORTC Q30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>every 3wk (every cycle)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>NCI CTCAE v3.0 Neutropenia, leucopenia, thrombocytopenia, hepatotoxicity, renal toxicity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">53</enrollment>
  <condition>Locally Advanced Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>genexolPM + cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>genexolPM + cisplatin</intervention_name>
    <arm_group_label>genexolPM + cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  locally advanced head and neck squamous cell carcinoma

          -  oral cavity, oropharynx, hypopharynx, larynx

          -  measurable lesion

          -  unresectable

          -  age 18 or more

          -  ECOG 0 or 1

        Exclusion Criteria:

          -  distant metastasis

          -  pregnancy

          -  prior chemotherapy or radiation therapy

          -  2ndary malignancy

          -  other unfit medical condition
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Se-Hoon Lee, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhumsuk Keam, MD</last_name>
    <phone>82-2-2072-7215</phone>
    <email>bhumsuk@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bhumsuk Keam, MD</last_name>
      <phone>82-2-2072-7215</phone>
      <email>bhumsuk@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>May 23, 2014</lastchanged_date>
  <firstreceived_date>August 30, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Se-Hoon Lee</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
